We are IntechOpen,

the world’s leading publisher of

Open Access books
Built by scientists, for scientists

7,100
Open access books available
189,000
International authors and editors
205M Downloads

Our authors are among the

154
Countries delivered to
TOP 1%
most cited scientists
12.2%
Contributors from top 500 universities

Selection of our books indexed in the Book Citation Index

in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?

Contact [Link]@[Link]
Numbers displayed above are based on latest data collected.
For more information visit [Link]
Chapter

Artificial Liver Support Systems

Maiko Alejandro Tavera Díaz

Abstract

Acute liver failure and acute-on-chronic liver failure, regardless of the etiology,
generate an inflammatory response in the liver parenchyma and systemic inflammatory
response, as well as anti-inflammatory counterregulatory mechanisms that condition
a state of immunomodulation, a condition that favors sepsis and septic shock. The
increase in Von Willebrand factor and the increase in cellular traffic of monocytes
and macrophages in the hepatic sinusoids, altering hepatic hemodynamics, is another
mechanism of damage. Artificial liver support therapy represents an alternative in
the support of these patients when medical treatment does not achieve the objectives.
MARS, Prometheus, and SPAD favor detoxification. Plasma exchange and DPMAS
are alternatives to limit the inflammatory response, eliminate Von Willebrand factor,
and improve survival. Current evidence recommends the use of plasma exchange or
combined extracorporeal support therapies as an alternative to achieve organ recovery
or as a bridge to liver transplantation.

Keywords: acute liver failure, acute-on-chronic liver failure, artificial liver support
systems, liver diseases, plasma exchange

1. Introduction

Liver diseases represent the tenth leading cause of death in the world and one of
the leading causes of disability and years of life lost. Regardless of the etiology of liver
disease, only 10% of those who require an organ get a transplant.
Acute liver failure and acute-on-chronic liver failure are serious pathologies, which
despite the treatment of the cause and the associated complications, many of them
require organ support through an artificial or biological system until the recovery of
the liver is achieved. Liver support systems act as a bridge to liver transplantation [1].

2. Spectrum of liver diseases

Liver diseases are associated with poor outcomes and are often considered a medi-
cal emergency due to the severity and complications associated with mortality.
In the spectrum of the form of presentation, three entities are evident [2]:

1. Acute liver failure (ALF) in the context of health and normal liver function as-
sociated with a new noxa that determines the damage.

1
Updates on Hemodialysis

Figure 1.
Acute liver diseases are described: acute hepatitis, acute liver injury, and acute liver failure.

2. Acute-on-chronic liver failure (ACLF) develops on a background of chronic liver

disease without cirrhosis or with underlying cirrhosis.

3. Known cirrhosis suffering from decompensation of liver function.

See Figure 1.

3. Acute liver failure

It represents a form of critical illness, potentially fatal, that occurs in 1 case per
million, and the incidence is variable in each continent: Europe 0.62, Asia 6.2–23.8,
USA 0.19 cases per 100,000 person-years [3]. The most frequent cause is paracetamol
poisoning, followed by undetermined causes, drug-induced injury (DILI), and
hepatitis [4].
Acute liver failure (ALF) represents severe liver damage (transaminase elevation
x 3) with the development of hepatic encephalopathy preceded by jaundice. This
time interval from jaundice to the presence of encephalopathy [5] allows its clas-
sification (Table 1):

Author O’grady AIEH

Hyperacute 1–7 days < 10 days

Acute 8–28 days 10–30 days

Subacute 5–12 weeks 5–24 weeks

Chronic > 26 weeks > 24 weeks

Table 1.
Classifications of acute liver failure, which correspond to the time interval from the onset of jaundice to the
development of encephalopathy.

4. Acute on chronic liver failure

The development of acute liver failure on chronic failure (ACLF) occurs at any
stage of the spectrum of chronic liver disease without cirrhosis or with compensated
or decompensated liver cirrhosis [6], in which there are one or several precipitating
2
Artificial Liver Support Systems
DOI: [Link]

Figure 2.
In the spectrum of chronic liver disease without cirrhosis or with compensated or decompensated liver cirrhosis,
the clinical condition that favors exposure to a hepatic or extrahepatic precipitant generates an inflammatory
response that induces the development of multiple organ failure.

events in the liver (alcohol ingestion, DILI, hepatitis, hepatic ischemia, liver surgery)
or extrahepatic (acute bacterial infection, paracentesis without albumin, major
surgery), which cause the development of multiple organ failure with the increased
mortality between 28 and 90 days (Figure 2) [7].
There is no universal definition, there are at least four consensuses that define it
and the prevalence differs from continent to continent, in USA 10, EU 20.1, ASIA 5.1
cases per 1000 person-years [8].
The most agreed definitions of ACLF are mentioned below: (Table 2) [7],
The severity of ACLF is measured by the degree of organic dysfunction through
the CLIF-SOFA score in different cohorts of three subjects (CANONIC, PREDICT,
KACLIF, COSSH, MAHMUD, HERNAEZ) showing us that the analytical alteration

APASL EASL-CLIF NACSELD WGO

Acute liver damage Pre-existing Syndrome Syndrome in CLD with or

manifesting as Jaundice CLD acute characterized by without previously diagnosed
(BT 5 mg/dl) and deterioration, acute deterioration cirrhosis is characterized by
coagulopathy (INR > 1.5), related to a in a patient with acute hepatic decompensation,
complicated within precipitating cirrhosis, due resulting in liver failure
4 weeks with ascites event associated to an infection, (jaundice and prolonged INR)
and encephalopathy in a with multiorgan developing failure and failure of one or more
patient with diagnosed or failure with high of two or more extrahepatic organs with high
undiagnosed chronic liver mortality at 28 extrahepatic organs. mortality at 28 and 90 days.
disease. and 90 days.
Asian Pacific Association for the Study of the Liver (APASL), European Association for the Study of Chronic Liver
Failure (EASL-Clif), North American Consortium for the Study of End-Stage Liver Disease’s definition of acute-on-
chronic liver failure, and World Gastroenterology Organization (WGO).

Table 2.
Characteristics of definitions of ACLF developed by four different consortia.

3
Updates on Hemodialysis

is significant insofar as to the presence of leukocytosis, PCR, increases in TNF alpha,

and IL-8 in statistically significant values in patients with ACLF when compared with
decompensated or compensated cirrhosis. Likewise, it is observed that transplant-
free mortality is higher in patients with ACLF [8].

5. Pathophysiology

5.1 Inflammatory response

5.1.1 Acute liver failure

Regardless of the etiology of liver damage, apoptosis and hepatocyte necrosis

are generated, which allows the release of damage-associated molecular patterns
(DAMPs), such as micro-RNA 122, high mobility protein 1 (HMGB1), Keratin 18,
which bind to toll-like receptors (TLR4) of Kupffer cells, which induces the release of
cytokines.
Activation of the Kupffer cells induces the release of cytokines, which stimulates
the recruitment of monocytes and induces an intrahepatic inflammatory phenotype,
with sequestration of platelets and amplifying the inflammatory response. The
inflammatory process is not limited to the liver, this induces a systemic inflammatory
response (SIRS), and a counterregulatory mechanism called compensatory anti-
inflammatory response syndrome (CARS) is induced, the latter conditions a state of
immunomodulation, which explains the high risk of infections, risk of sepsis, multi-
organ failure, and worsening of encephalopathy (Figure 3) [9].
Neopterin formed by macrophages, monocytes, and activated dendritic cells
has been described; it is considered a marker of inflammation in ALF due to

Figure 3.
A) Regardless of the etiology of the liver injury, the release of DAMPs is generated, recognized by the TLR4 of
Kupffer cells. B) Activated Kupffer cells release cytokines, which stimulate monocyte migration, amplifying the
inflammatory response within the liver. C) Inflammation is not limited to this organ and generates SIRS; likewise,
a counterregulatory mechanism (CARS) is stimulated, which leads to a state of immunoparalysis and increases
the risk of infections. D) Albumin in its oxidized form contributes to the perpetuation of the inflammatory
state. E) Damage to the stellate cells of the hepatic sinusoids decreases the release of ADAMTS 13, increases the
expression of VWF multimers, favors platelet aggregation that predisposes to the formation of microthrombi, and,
together with the increase in monocyte and macrophage trafficking, alters hepatic circulation.

4
Artificial Liver Support Systems
DOI: [Link]

acetaminophen. It is evident that the increase in neopterin and sCD163 correlates with
SIRS, greater clinical severity measured by SOFA score, and with the requirement of
liver transplantation [10]. The aforementioned supports the increase in mononuclear
cell activity and the increase in the inflammatory response in ALF.
Acute liver failure has great potential to develop multi-organ complications
(cerebral, respiratory, metabolic, hematological, hemodynamic, infectious, and
renal) despite supportive management, many of them do not stabilize and lead to an
increase in mortality. In this critical condition, extracorporeal liver support therapies
are used until the recovery of liver function, which, in some series, reaches 60% of
acute patients and without reaching transplantation [11].

5.1.2 Acute chronic liver failure

It represents the spectrum of chronic liver disease without cirrhosis or with com-
pensated or decompensated cirrhosis, in which a hepatic or extrahepatic precipitating
factor triggers a persistent inflammatory response that induces the development.
TNF alpha and activated stellate cells, allowing nitric oxide secretion, further
damage hepatocytes and cause splanchnic vasodilation. The endothelin released
from endothelial cells decreases the expression of cluster of differentiation (CD) and
human leukocyte anti-DR (HLA), conditions an environment of TL reg inhibition,
and lowers LTH 17 activation. This conditions a state of “Ineffective Immunity,”
dysfunctional cells, decreased phagocytic activity, increased anti-inflammatory
cytokines, and release of reactive oxygen species (ROS) [12].
ACLF conditions a SIRS state in the first 7 days from the onset of the symptoms
and after 10–14 days, a state of immunosuppression due to anti-inflammatory

Figure 4.
A) In chronic liver disease without cirrhosis and in compensated or decompensated cirrhosis, they generate the
favorable environment for the arrival of PAMPs in the enterohepatic circulation, mitochondrial stress, apoptosis,
and necrosis typical of liver disease, regardless of the etiology, allowing the release of DAMPs. Both molecules bind
to TRL4 receptors of Kupffer cells, which are activated and release cytokines with hepatic and systemic impact.
B) The intrahepatic inflammatory response and the release of chemokines induce chemotaxis of monocyte-
derived macrophages from the systemic circulation to the liver at sites of injury. C) Albumin in the oxidized
form contributes to the perpetuation of the inflammatory state. D) Damage to the stellate cells of the hepatic
sinusoids decreases the release of ADAMTS 13 and increases the expression of VWF multimers that favors platelet
aggregation and stimulates phagocytosis of these molecules by macrophages, increasing cell size and increasing the
number of cells. Cell traffic contributes to lower liver perfusion.

5
Updates on Hemodialysis

cytokines (CARS) is generated, increasing the risk of sepsis, septic shock, and
multiple organ failure (Figure 4) [13].
The severity of ACLF measured by CLIF-SOFA has a direct relationship with mor-
tality. The measures used in the management with crystalloid solutions and human
albumin, and the use of vasoactive agents are a necessity to meet the hemodynamic
objectives, anti-encephalopathy measures, and anti-cerebral edema. The need for
transfusion of blood products and the support of mechanical ventilation and infec-
tion control represent the supportive management of these patients. Many of them,
despite the optimization of the measures implemented, require extracorporeal liver
support therapy, which, as in acute liver failure, has the clear objective of limiting the
inflammatory response that perpetuates cell damage, decreasing macrophage activa-
tion that conditions the permanent inflammatory response.

5.2 Oxidation of albumin

Albumin is a high molecular weight protein (MW 66.5 kD), which is a fundamen-
tal determinant since it provides 75% of the oncotic pressure, necessary to maintain
fluids in the intravascular compartment, and represents 54% of the plasma proteins,
with a hepatic synthesis rate of 150 m/kg/day [14]. Albumin is formed by a polypep-
tide chain of 585 amino acids, divided into three domains I, II and III. Each domain
is subdivided in types A and B, it is composed of 35 cysteine residues, of which 34
residues form 17 disulfide bridges and leave the cysteine residue (Cys) 34 free to
interact with others molecules (Table 3) [15].
The important functions of albumin include being a regulator of extracellular
fluids, it allows the reversible transport of endogenous products, such as fat-soluble
hormones and free fatty acids, transporting unconjugated bilirubin, and exogenous
products such as metals, drugs, and drugs. It also fulfills a function important in
PH control, buffering non-volatile acids, and competitive binding to calcium ions.
Antioxidant properties are described because it is a source of reduced sulfhydryl
groups with properties to eliminate ROS, with anti-inflammatory and endothelial
protection effects [14].
Albumin mostly circulates in a reduced state, called human mercaptoalbumin
(HMA) with a free thiol group at residue Cys 34, to which ROS and nitrogen bind,
allowing their uptake and removal of free radicals. Albumin can undergo several post-
translational modifications in physiological or pathological conditions, which under-
goes oxidation through disulfide bonding between Cys34 and sulfhydryl-containing
compounds such as glutathione, homocysteine, and cysteine. This reversibly oxidized
form of albumin is called non-mercaptoalbumin type 1 (HNA-1) and the complete
and irreversible oxidation of Cys 34 albumin to sulfonic or sulfinic acid confers the

Domain I Domain II Domain III CYS 34

Uremic toxins Halotan Bilirubin Nitric oxide

Thyroxin Propofol Hemin
Warfarin Ibuprofen Doxorubicin
Uremic toxins
Thyroxin

Table 3.
Each albumin domain allows the transport of different substances, and the CYS 34 residue has the capacity to
eliminate ROS.

6
Artificial Liver Support Systems
DOI: [Link]

name non-mercaptoalbumin type 2 (HNA-2) [16, 17]. Other forms of modified

albumin are also described, such as ischemia-modified albumin (IMA), in which it
undergoes a conformational change in the N-terminal portion, decreasing the metal
transport capacity, and the IMA/albumin ratio is also increased in patients. with
cirrhosis and ACLF, described as a marker associated with higher mortality. Other
forms of cystei-nylated, glycated and truncated modified alumina are mentioned,
all the described forms of oxidized albumin lose the capacity to transport molecules
and detoxify, increasing the free component of many toxic substances that alter the
functions of organs and systems [17].
The expression of non-mercaptoalbumin types 1 and 2 has an effect on the
activation of mononuclear cells by stimulating the release of cytokines (IL 1β, IL 6,
IL 8, and TNF-α), amplifying or perpetuating the inflammatory response, by which
a relationship between the levels of oxidized albumin and the pro-inflammatory state
exists. In a cohort study of 79 patients, non-mercaptoalbumin type 1 phosphorylated
the mitogen-activated protein kinase (MAP) p38α [18] was observed, which increases
the activity of the transcription factor NF-κB, induces the production of cytokines,
and also increases the production of inflammatory COX2 eicosanoides such as throm-
boxane A 2 (TXA2), leukotriene B 4 (LTB4), and prostaglandin G2 (PG2) [18].
We see that albumin oxidation is a mechanism that by itself induces and perpetu-
ates inflammation in patients with decompensated cirrhosis and acute-on-chronic
liver failure, which opens the way for the search for other applications of extracorpo-
real liver support therapies.
In a randomized crossover design trial of eight patients with ACLF, who under-
went alternate eight treatments with MARS and Prometheus, non-mercaptoalbumin
types 1 and 2 levels were measured and found to be elevated, and there was a transient
change in status redox, from non-mercaptoalbumin to mercaptoalbumin that lasted a
short time, returning to the oxidized forms of albumin after 24 hours [19].
There are few studies that evaluate extracorporeal liver support techniques as
an alternative for albumin detoxification or regeneration. The Molecular Adsorbent
Recirculating System (MARS) was found to be useful in removing substances bound
to albumin and improving hepatic encephalopathy, but in a small study of 34 MARS
patients [20], it did not show benefit in improving functional capacity or regenerat-
ing capacity and normal functionality of albumin. It is possible that liver damage and
inflammation lead to irreversible damage to albumin and extracorporeal liver sup-
port techniques based only on albumin recirculation with small-capacity and easily
saturated adsorbents.

5.3 Von Willebrand factor and ADAMTS 13 effect on ALF and ACLF

The Von Willebrand factor (VWF) is formed by endothelial cells, megakaryo-

cytes, and hepatocytes in the latter when the hepatic injury occurs [21]. This factor is
cleared by macrophages and stored in endothelial cells, in Weibel-Palade bodies, and
in the alpha granules of megariocytes.
VWF has MW 10,000 KD and is released at sites of vascular damage in response
to secretion stimuli, such as thrombin, endothelial stress, vasopressin, or its synthetic
analog desmopressin.
In ALF and ACLF, it generates damage to the endothelial cells of the liver sinusoids
and releases VWF multimers, which bind to Domain A1, Glycoprotein IB Alpha
(GPIbα), and GPIIb/IIa of platelets, and subendothelial collagen, allowing adhesion,
platelet aggregation, and sequestration, giving rise to the formation of microthrombi
7
Updates on Hemodialysis

and generating intrahepatic hemodynamic changes and liver ischemia, cell necrosis,
worsening of liver function, activating innate immunity, and contributing to the
development of multi-organ dysfunction [22].
Basic experimentation studies in mice with ALF by paracetamol show an increase
in VWF and platelet aggregation after 48 hours after drug exposure [21, 23]. In a
prospective study of patients with ACLF, increased VWF was correlated with higher
MELD and SOFA scores [22].
Damage to stellate cells determines a lower release of ADAMTS 13. Under normal
conditions, this disintegrin metalloproteinase cleaves the TYr 1605-Met 1606 bond of
the VWF A2 domain, degrading the VWF multimers. In ALF and ACLF, low levels of
ADAMTS 13 [24, 25] are identified, causing less cleavage of the VWF multimeters.
These new links require further studies on the use of VWF inhibitors, ADAMTS 13
supplementation, or the use of extracorporeal liver support therapies for the removal
of VWF multimers [25] and limiting liver damage.

5.4 Macrophage activation

When hepatocyte damage is generated, Kupffer cells express two phenotypes:

proinflammatory where Kupffer cells release cytokines (IL-1β, tumor necrosis factor
(TNF)-α and Ccl2), the chemokine Ccl2 and the activity of plasmin during liver
tissue damage, stimulating the chemotaxis of monocyte-derived macrophages from
the systemic circulation to the liver at sites of injury, in order to control intrahepatic
trafficking, endocytosis, phagocytosis, and phenotype switching to one of repair with
dedifferentiation of macrophages to fibroblasts [26].
Under healthy conditions, macrophages constitutively present CD163 and CD206
receptors. During the proinflammatory phase of ALF and ACLF, a detachment of
soluble sCD163 and sCD206 is generated, and the severity of ALF, ACLF, and mortal-
ity is considered biomarkers [27], which may play a role in making early medical or
transplant decisions.
Macrophages are persistently activated in the presence of VWF and these cells are
located in low-pressure sinusoids, being the parking residence of activated macro-
phages and which, together with microthrombi, alter hepatic hemodynamics.
The lines of study in inhibitors of macrophage chemotaxis, the use of extracorpo-
real liver purification therapies in the elimination of cytokines and chemokines, and
achieving immunomodulation that allows limiting the migration of mononuclear cells
to the liver and mitigates the damage may be promising.

5.5 Extracorporeal liver support therapy

Liver support therapies have been used with the aim of trying to replace the loss of
important functions of the liver, and these systems are limited to detoxification and to
reduce the inflammatory response.

5.5.1 Types of extracorporeal liver support therapy

They are divided into artificial and biological [28]. In this review, the description
of artificial therapies will be made (Table 4).
The artificial liver support system allows the removal of water-soluble toxins, such
as ammonium, urea, creatinine, iron, aromatic amino acids, trypophan, and also fat-
soluble toxins, such as bile acids, conjugated and unconjugated bilirubin, short and
8
Artificial Liver Support Systems
DOI: [Link]

Artificial Biological

1. MARS 1. ELAD®
2. Fractionated plasma separation and adsorption 2. BiologicDT
(Prometheus)
3. Hepa-Mate™
3. Single-pass albumin dialysis (SPAD).
4. TEAK-BALSS/HBAL
4. Hemoperfusion
5. AMC-BAL
5. Plasma exchange
6. HEPATASSIST SYSTEM
6. Plasma adsorption
7. Double plasma molecular absorption system
(DPMAS)

Table 4.
Classification of liver support systems.

medium chain fatty acids, benzoadiazepines endogenous, mercaptans, copper, nitric

oxide, indoyxisulfate, and protoporphyrin [29].
We consider that the removal of the mentioned toxicants with detoxification-only
approach does not generate the clear benefit due to the extensive mechanisms of
perpetuation of liver damage, it is possible that the traditional MARS, Prometheus
techniques are not good enough due to the smaller diameter of the beads, smaller
pore diameter, smaller amount of resin, and smaller adsorbent surface in the first two
and that the concentration of albumin used in MARS and SPAD is not sufficient, and
these details will be reviewed in each of the techniques extracorporeal support.

5.5.2 When to start extracorporeal liver support therapy?

The most agreed recommendations for the start of extracorporeal support are the
following [30]:

1. Severe acute liver injury regardless of cause.

2. Acute liver failure regardless of cause.

3. Acute on chronic liver failure.

4. Sepsis with severe liver injury.

5. Acute kidney injury with criteria for hepatorenal syndrome that does not re-
spond to treatment with Terlipressin and albumin.

6. Primary nonfunction and delayed graft function following liver transplantation.

7. Delayed graft function in simultaneous liver kidney transplantation.

8. Post-hepatectomy liver failure.

9. Hypoxic liver injury.

10. Refractory pruritus.

9
Updates on Hemodialysis

5.5.3 Artificial extracorporeal liver support systems

[Link] Molecular adsorbent recirculating system (MARS)

This purification system allows the elimination of toxins bound to albumin and
water-soluble toxins. The blood that is extracted by catheter circulates at a blood flow
of 200 ml/min and is placed in contact with the high permeability MARS® FLUX
2.1 filter (60 kD) and 600 ml of dialysate albumin circulates counter currently with
pumped 150 ml/min. This recirculated albumin is placed in contact with the diaFLUX
1.8 filter and with the conventional dialysis bath of the Prismaflex System, allowing
the elimination of water-soluble molecules, and the regenerated albumin circulates
through the activated carbon cartridge (diaMARS® AC250) that captures cationic
toxins and then goes to a second resin cartridge (diaMARS® IE250) that captures
anionic toxins. The procedure is performed with an average of 8 hours up to date,
with the aim of reducing total bilirubin by more than 25% in each session, achieving a
reduction in nitrogen and ammonia and reversing encephalopathy (Figure 5).
In the FULMAR study [31], a randomized control trial (RCT), a multicenter study
that included 102 ALFs on the liver transplant waiting list, of which standard medical
treatment (SMT) vs. SMT and MARS were compared, in this study, it was seen that
overall survival at 6 months, transplant-free survival at 6 months, and survival at
1 year were not significantly different in both groups, but transplant-free survival
was better in those patients who received more than 3 MARS sessions (p = 0.001)
when compared to STM. In relation to other outcomes, there was no improvement in
encephalopathy between both treatment groups, but a significant decrease in biliru-
bin, creatinine, and lactate values was achieved compared to SMT, and it is a valuable
therapy in patients who are not candidates for liver transplantation.
In the RELIEF study [32], a multicenter RCT, recruited 189 patients with decom-
pensated cirrhosis (total bilirubin > 5 mg/dl, hepatorenal syndrome or hepatic
encephalopathy grade II) and compared STM vs MARS and STM treatment, there

Figure 5.
Molecular adsorbent recirculating system (MARS). A) Once the patient’s blood enters the high permeability (60
kD) MARS® FLUX 2.1 filter, 600 ml of dialysate albumin circulates in a countercurrent direction with pumped
150 ml/min. B) Then, the recirculated albumin is directed to the diaFLUX 1.8 filter and with the conventional
dialysis bath of the Prismaflex system, allowing the elimination of water-soluble molecules. C) Next, the
regenerated albumin circulates through the activated carbon cartridge (diaMARS® AC250) that captures cationic
toxins. D) It is then directed to a second resin cartridge (diaMARS® IE250).

10
Artificial Liver Support Systems
DOI: [Link]

were no differences in survival at 28 and 90 days, in the survival analysis by sub-

groups there were no differences in survival either, without differences in the length
of stay in intensive care and hospital stay, but a significant decrease in bilirubin and
creatinine values was achieved in favor of therapy MARS. The lack of evidence is
attributed, whether it is related to the heterogeneity in the definition of ACLF, small
sample size, low dose of therapy, rapid saturation of the cartridges and albumin, or
that MARS therapy does not adjust to the severity of many patients.
A meta-analysis published by Arjun Vaid et al. [33] review 10 RCT and one no RCT
and use the Jadad scale to assess the quality of the studies, recruited patients, includ-
ing ALF and ACLF, and receive MARS from one to 10 sessions, lasting between 6 and
8 hours. The outcomes show a significant decrease in bilirubin levels (p = < 0.001),
there was also improvement in encephalopathy (p = <0.001), but MARS therapy did
not reduce mortality (p = 0.62), in the analysis by subgroups when performing more
than three sessions or increasing the concentration of albumin >20%, which did not
influence the reduction of mortality.
Rafael Banares et al. [34], published a high-intensity MARS meta-analysis,
recruited 285 patients with ACLF and called high-intensity MARS when they received
more than 5 sessions. In the high intensity group, 10-day survival (p = 0.001) and 30
days (p = 0.041) is higher and there was a significant decrease in the MELD score,
bilirubin, creatinine, and encephalopathy improvement, compared to the low inten-
sity group, when the number of sessions was less than 5 MARS sessions.
One recently published DELPHI consensus of international experts [35] recom-
mends extracorporeal albumin dialysis (ECAD) in the MARS modality should
be started in the early stages of grade II encephalopathy or within 24–48 hours of
refractory hepatic encephalopathy and when indications for liver transplantation are
present and more than 3 sessions lasting 8 hours are recommended. The reported
evidence mention improvement in survival at 21 days in ACL due to acetaminophen,
but no benefit at 6–12 months. The use of ECAD is not recommended in patients in
the late stages of ALF where multiple organ dysfunction is already expressed.

6. Prometheus

It is a fractionated plasma separation and adsorption system, the blood extracted

through a catheter circulates through an AlbuFlow® AF01 filter, with a high screen-
ing coefficient (250 kD), which separates the albumin from the blood, the first to
pass through the plasma to an adsorbent cartridge Prometh® 01 contains a neutrally
charged, highly porous resin that absorbs bile acids, aromatic amino acids, and
phenols. Then, the plasma and the albumin circulate through a second Prometh®
02 cartridge, which is an anion exchange resin in the form of chloride that allows the
absorption of bilirubin, and following the sequence of the circuit, the blood plasma
and the detoxified albumin are returned to the Fresenius® helixone high-flow filter
to remove water-soluble toxins (Figure 6).
In the HELIOS study [36], an RCT included 145 patients with ACLF and compared
SMT vs. SMT and Prometheus, in the survival outcomes at 28–90 days there were
no statistical differences, the mean until death had no differences, and the severity
of MELD and encephalopathy improved in the Prometheus group, in the univariate
analysis there was no improvement in survival in patients with hepatorenal syn-
drome, the length of stay in critical care and the hospital was similar in both groups,
and in the analytical the only value that improved it was the bilirubin.
11
Updates on Hemodialysis

Figure 6.
Fractionated plasma separation and adsorption (Prometheus). A) The blood extracted through a catheter
circulates through an AlbuFlow ® AF01 filter. B) Albumin and separated plasma pass to a Prometh® 01
adsorbent cartridge. C) Albumin then circulates through a second Prometh® 02 cartridge. D) Following the
circuit sequence, blood plasma and detoxified albumin are returned to the Fresenius® helixone high-flow filter.

7. Mars and prometheus theory combination

In a randomized crossover design study, eight patients with ACLF who underwent
MARS and Prometheus on alternate days were evaluated, completing 17 sessions for
each of the two artificial liver support systems. Cytokine measurements were per-
formed in healthy controls and in patients with ACLF, evidencing elevated IL-6, IL-8,
IL-10, TNF-α, and sTNF-αR1 values in the latter group. This work shows that there
was no significant decrease in cytokines at the end of treatment and other reviews
with both artificial support systems report similar results. The low efficiency is
attributed to the high rate of cytokine production due to multiple mechanisms of the
perpetuation of the inflammatory response, the greater saturation of the cartridges,
or less adsorbent capacity [37–39].

8. Single-pass albumin dialysis (SPAD)

This purification system that uses the physical foundation of diffusion with a dialy-
sis bath enriched with albumin in 3–4% concentrations that act as a binder for sub-
stances bound to proteins. This technique uses a continuous renal replacement therapy
(CRRT) machine in continuous venovenous hemodialysis modality, with a dialysate
flow of 700–1000 ml/min. The dialysate flow with albumin will allow the capture of
lipophilic molecules present in the patient’s blood that will bind to the albumin that
circulates in the countercurrent direction to the blood flow through the filter, allowing
the elimination of bilirubin, bile acids, and nitrogen acids (Figure 7).
12
Artificial Liver Support Systems
DOI: [Link]

Figure 7.
Single-pass albumin dialysis (SPAD). A) The technique uses a continuous renal replacement therapy (CRRT)
machine in continuous venovenous hemodialysis modality, with a dialysate flow of 700–1000 ml/min, the
dialysate is enriched with 3–4% albumin.

This technique does not use additional cartridges or other extracorporeal circula-
tion machines and can be performed in low-income countries.
There is evidence that SPAD allows a significant decrease in bilirubin similar to
MARS, but it failed to lower bile acid and cytokine values [40], considering that the
modality used is continuous venovenous hemodialysis and due to the screening coef-
ficient of conventional membranes does not allow clearance of cytokines [41].
In a randomized crossover trial [42], of 34 patients with ACLF, who underwent
dialysis with albumin, assigning the first session randomly to MARS or SPAD
modality, the second session was assigned to a different therapy. Both therapies
achieve a significant decrease in bilirubin, bile acids, and a greater decrease in
creatinine with MARS. The significant decrease in fibrinogen in SPAD was identi-
fied as an adverse effect, and both therapies decreased hemoglobin, hematocrit,
and platelets. Both therapies are considered comparable, with the advantage of the
lower costs of SPAD.

9. Plasma exchange

The plasma exchange (PE) is an extracorporeal purification technique that is

carried out by centrifugation or filtration. This last technique uses a high permeability
membrane with a large pore size greater than 0.3 microns, allowing the separation
of plasma and the removal of medium and medium molecules with high molecular
weight, such as cytokines and immunoglobulins (Figure 8).
Within the pathophysiological mechanisms of acute and chronic liver injury, the
increase in Von Willebrand multimeters stands out due to a decrease in the release of
ADAMTS 13 as a result of stellate cell damage. The increase in the Von Willebrand
factor multimeters intervenes in platelet aggregation in the hepatic sinusoids and
conditions the migration of macrophages for their phagocytosis, and both alterations
condition a deterioration of the vascular flow of the liver and also condition a greater
inflammatory response.
13
Updates on Hemodialysis

Figure 8.
Plasma exchange (PE). The technique uses a high permeability membrane with a large pore size that allows
plasma separation and replacement of the extracted volume is performed with 5% albumin or fresh frozen plasma.

Klaus Stahl et al. [43], in a single-center prospective study, demonstrated in

31 patients with sepsis that plasma exchange increased ADAMTS 13 activity and
decreased VWF antigen, confirming the therapeutic application of this imbalance.
The RCT described by Larsen et al. [44], through an RCT in 182 patients with ALF,
evaluated SMT vs. SMT and high volume plasma exchange for 3 days (8–12 L) with
replacement with fresh-frozen plasma in equivalent volume. In the consulted evidence,
the primary outcome that corresponds to liver transplant-free survival during the
hospital stay was higher in the group that received plasma exchange (p = 0.0083), and
survival in those who did not receive a transplant and received plasma exchange was
better when compared with those who were not transplanted and did not receive plasma
exchange. In the group with plasma exchange, the hemodynamic variables improved,
noradrenaline doses were reduced, the SOFA and Clif SOFA severity scores improved,
and the analysis showed improvement in coagulation times, decreased bilirubin, alanine
aminotransferase (ALT), and ammonium. When the inflammatory response is assessed,
plasma exchange reduces DAMPs, TNF alpha, IL 16 at 48 hours, and IL 18, and decreases
in CD 163, CD 64, and CCR7, which indicates less mononuclear cell traffic.
High-volume plasma exchange carries risks with high replacement volume and could
worsen cerebral edema, Maiwall et al. [45], report a prospective open-label RCT study
where 40 patients with ALF were recruited, each group was divided into 20 patients
for SMT vs STM and standard plasma exchange (1–1.5 plasma volumes per PE session).
The outcome of transplant-free survival at 21 days was higher in the group with plasma
exchange (p 0.04). In the secondary outcomes, there is evidence of a lower inflammatory
response and a smaller diameter of the optic nerve sheath with a predictor of decreased
cerebral edema, hemodynamic variables, vascular resistance index improved, SOFA
score decreased, there was a decrease in lactate and bilirubin values they also decreased.
When inflammation data are analyzed, a decrease in innate immunity cytokines and an
increase in anti-inflammatory cytokines, a significant decrease in DAMPs, endotoxins,
and a decrease in VWF are evident in the group that received exchange plasma.
In a retrospective study [46] of 50 patients with alcohol-related acute on
chronic liver failure (A-ACLF), low-dose corticosteroid treatment was compared
14
Artificial Liver Support Systems
DOI: [Link]

Points Liver Total bilirubin PT-INR Infection Hepatic

cirrhosis (μmol/L) encephalopathy

0 No < 425 < 2.0 Non- No

spontaneous
bacterial
peritonitis
(SBP)

1 And it is 425–650 2.0–2.5 Yes SBP I–II

2 And it is ≥ 650 ≥ 2.5 SBP plus other III–IV

site infection

Table 5.
PALS score predictive score of short-term prognosis for patients treated with plasma exchange.

with low-volume plasma exchange (LVPE) (0.5–1 plasma volumes per PE session)
vs. SMT, Kaplan-Meier survival analysis shows better survival in the first year
(P = 0.03) and there were lower levels of VWF in the plasma exchange group.
Further large randomized control trials are needed to evaluate the efficacy of
LVPE in ACLF.
In a systematic review and meta-analysis [47] of 16 RCTs that included 1670
patients with ALF, the efficiency of each therapy was compared to SMT, ELAD,
MARS, Prometheus, and plasma exchange. It is shown that the probability of having
greater overall survival at the first and third month as well as transplant-free survival
at 3 months was better with exchange plasma.
The European Association for the Study of the Liver [11], in the guidelines for the
management of acute liver failure, recommends plasma exchange improves trans-
plant-free survival and modulates immune dysfunction with evidence level I, grade
of recommendation 1. and recommends early onset and in those who will not undergo
liver transplantation with evidence level I, grade of recommendation 2.
One DELPHI consensus of international experts [35] recently published, in
relation to PEHV, is recommended due to the greater transplant-free and in-hospital
survival. The PLAS score [48] uses two derivation and validation cohorts of patients
with ACLF, whose predictive value for 3-month mortality when the score was greater
than 6 points (AUC 0.80 derivation cohort and 0.78 validation cohort) has better
performance when it is compared with the model for end-stage liver disease (MELD)
and also with other mortality scores. The variables taken into account for stratifica-
tion are liver cirrhosis total bilirubin, PT-INR, infection, and hepatic encephalopathy.
The score goes from a minimum of 0 to a maximum of 9, it is called grade I: score of
0–2, grade II: 3–5, grade III: 6–9 (Table 5).
Extracorporeal liver support therapy is not recommended in patients who develop
platelet counts <40,000/mm3, INR > 2.5, and fibrinogen <1 g/L, which would
increase the risk of bleeding [35].

10. Plasma adsorption perfusion

Plasma adsorption perfusion (PAP) uses a CRRT or intermittent hemodialysis

machine. Once the blood comes out through the catheter with a blood pump flow at
150 ml/min, it allows the blood to enter the plasma exchange filter where it allows the
separation of the plasma by filtration. The obtained plasma is mobilized by a second
15
Updates on Hemodialysis

Figure 9.
Plasma adsorption perfusion (PAP). A) The blood exits through the catheter with a blood pump flow at 150 ml/
min, it allows the blood to enter the plasma exchange filter where it allows the separation of the plasma by
filtration. B) The obtained plasma is mobilized by a second pump at 25–50 ml/min and enters a cartridge made
of the styrene-divinylbenzene copolymer.

pump at 25–50 ml/min and enters a cartridge made of styrene-divinylbenzene copo-

lymer, with the capacity to adsorb bilirubin, bile acids, and cytokines. This technique
has some advantages over the other techniques mentioned, such as it does not require
the use of exogenous plasma or albumin infusion, it does not eliminate coagulation
factors, and it is less expensive than MARS (Figure 9).
A single-center retrospective study [49] evaluated the performance of three
therapies (MARS, PAP, and PE) and recruited 103 patients with hyperbilirubinemia
due to ALF and ACLF, and extracorporeal liver support therapy was started when the
total plasma bilirubin level > 20 mg/dl, or an increase in bilirubin level of more than
2 mg/dl per day for 4 days. When total bilirubin removal is assessed in these therapies,
a 25% decrease is considered the optimal value. A greater decrease in bilirubin was
seen with PE (35 ± 13%) followed by PAP (30 ± 12%) and the lowest percentage with
MARS (24 ± 14%), and the values of transaminases and coagulation tests were not
different between the three techniques. In this review, the costs per treatment are
mentioned, being the most economical PE, followed by PAP and the most expensive
MARS due to equipment and the long time the therapy takes. It is important to men-
tion that an advantage of MARS over the other techniques mentioned is its application
in acute kidney injury (AKI) that requires renal support therapy.

11. Double plasma molecular adsorption system

The double plasma molecular adsorption system (DPMAS) modality has the
particularity of using a CRRT or intermittent hemodialysis machine with second
roller pumps. Once the blood is drawn through the catheter with a blood pump flow
of 150 ml/min, the blood passes through a high permeability filter to separate the
plasma and then, the separated plasma is driven by a second roller pump at 25–50 ml/
min, which enters a first BS330-JAFRON styrene-divinylbenzene cartridge with
anion-exchange resin and later the plasma goes through a second HA330 II-JAFRON
cartridge with neutral macroporous resin, to then be reconstituted by the plasma in
the blood that returns to the patient’s catheter (Figure 10).
The evidence consulted reports an RCT from China [50], which includes patients
with ALF and ACLF. They are randomized into two groups, 20 patients in the SMT
and PE group vs. 27 in the SMT and DPMAS group. The result in the primary outcome
shows a survival at 4–12 months is similar in both groups (p = 0.887), in the secondary
outcomes measurements of bilirubin and CRP are performed, which decrease more
16
Artificial Liver Support Systems
DOI: [Link]

Figure 10.
Double plasma molecular adsorption system (DPMAS). A) The blood extracted through the catheter enters
a high permeability filter to separate the plasma. B) The separated plasma is driven by a second roller pump
that drives the plasma into a first BS330-JAFRON cartridge made of styrene-divinylbenzene with anion-
exchange resin. C) Subsequently, the plasma passes through a second cartridge HA330 II-JAFRON with neutral
macroporous resin.

significantly with PE (p = 0.002), and the decrease in procalcitonin was similar in both
groups, greater hypoalbuminemia in the PE group. The increase in IL-6 is strikingly evi-
dent in both groups and is attributed to being a stimulatory factor in liver regeneration.
During a meta-analysis [51] of 11 articles on ACLF due to hepatitis B, where the
values of total bilirubin and albumin did not differ in both groups, ALT decreased
more in DPMAS+PE than, with PE alone, the levels of I international standardized
ratio (INR) and blood platelet (PT) were prolonged, but there were no significant
differences between the two groups. In this study, there was a lot of heretogenicity in
study quality which could lead to bias.
In another meta-analysis [52] of 11 RCT studies, including 1087 hepatitis B
patients with ACLF, comparing two treatment groups with DPMAS + plasma
exchange vs. plasma exchange alone, 90-day survival was higher with DPMAS +
plasma exchange (P = < 0.00001), and bilirubin and alanine aminotransferase values
after treatment were lower with DPMAS + PE (P = < 0.00001) and (P = 0.02),
respectively. There was no statistical significance in prothrombin activity (PTA), PT,
platelets (PLT), INR, and hemoglobin (HB).
In a retrospective controlled study [53] with DPMAS where 131 with ACLF for
hepatitis B were recruited, they were assigned to the plasma exchange group vs.
DPMAS + plasma exchange. Low-volume exchange plasma (2–2.4 L) was performed
with fresh-frozen plasma in the DPMAS group first and then with exchange plasma.
In the DPMAS + plasma exchange group, bilirubin decreases after the procedure, at 24
and 72 hours (P = < 0.05), and survival at 28 days was better (P = 0.043). Prospective
studies are needed to assess long-term survival.

12. Coupled plasma filtration with adsorption

Coupled plasma filtration with adsorption (CPFA) is a technique, which requires

a CRRT machine (Amplya), especially designed to combine the separation of plasma
from blood by a high-permeability polyethersulfone filter. Then, the separated plasma
circulates through a styrene cartridge-divinylbenzene copolymer and the purified
plasma is reconstituted with the blood, which is finally returned to a CRRT polyphen-
ylene hemofilter to remove water-soluble molecules (Figure 11).
17
Updates on Hemodialysis

Figure 11.
Coupled plasma filtration with adsorption (CPFA). A) Requires the separation of plasma from blood by a
high-permeability polyethersulfone filter. B) The separated plasma is circulated through a styrene-divinylbenzene
copolymer cartrige. C) The purified plasma is reconstituted with the blood, which is finally returned to a CRRT
polyphenylene hemofilter.

The Hercole trail [54], a non-randomized observational study that included

12 patients, 4 with ALF and 8 with ACLF, started APFC with total bilirubin val-
ues > 20 mg/dl and MELD >20 that did not improve with SMT. It is observed that CPFA
did not modify the SOFA and MELD score, the decrease in bilirubin (p = 0.0006) and
bile acids (p = 0.047) decreased significantly, but after the third hour, the filter was
saturated. Water-soluble molecules, such as water-soluble toxins, urea, and creatinine,
did not change significantly before or after PAFC, attributed to low convective volumes,
INR and aPTT values were prolonged, but bleeding was not reported. It is important to
mention that bilirubin rebound is expected to occur after the first session and ranges
from 10 to 40% and is characteristic of the multicompartmental model of bilirubin
kinetics, which occurs in any of the aforementioned therapies. It is a promising therapy,
which requires further evidence with randomized controlled trials.

13. Hemoperfusion

There are many reports of the use of hemoperfusion in liver failure since the 70s
and 80s.
Hemoperfusion is an extracorporeal therapy technique, which allows the passage
of blood through a filter with the adsorption capacity of molecules with molecular
weights from 5 to 50 kD, and the cartridges are classified according to a) composition
in natural compounds (carbons) and synthetics (divinylbenzene), b) surface and
volume, c) size, and d) selectivity.
The adsorption mechanisms attract solutes through different forces (hydrophobic
interactions, ionic attraction, hydrogen bonding, and Van der Waals interactions),
which allow the uptake of PAPMs, DAMPs, cytokines, chemokines, and multiple toxic
substances (drugs, poisons).
18
Artificial Liver Support Systems
DOI: [Link]

Figure 12.
Hemoperfusion. It is an adsorptive therapy that uses activated carbon cartridges or divinylbenzene resins.

The cartridges can be mounted in CRRT or in an intermittent hemodialysis (IH)

machine, and it can be coupled to CRRT, prolonged intermittent renal replacement therapy
(PIRRT), or IH modalities, to simultaneously perform both therapies (Figure 12).
In a retrospective study [55], the use of charcoal hemoperfusion in 13 patients with
refractory pruritus in cholestatic, managed to reduce pruritus in 69% of patients and
in a numerical pruritus score performed before the start of therapy with a score of
9/10, decreased to 4/10, with an average of 5 sessions.
Stanje J et al. [56], in an in vitro two-compartment model established for the com-
parison of MARS vs. Cytosorb, water-soluble toxicants, such as creatinine, decreased
significantly with MARS (p = < 0.04), and the decrease in ammonia was more significant
with Cytosorb (p = < 0.05). Regarding the toxins bound to albumin, Cytosorb managed
to decrease the values of total and indirect bilirubin in statistically significant values (p = <
0.03) and the elimination of bile acids was comparable. The decrease in cytokines, such as
IL-6 and TNF-α with 6 hours of therapy, was significant with Cytosorb. More controlled
studies are required to support the results reported in experimental studies and case series.

14. Hepatorenal syndrome

Patients with advanced cirrhosis frequently show some degree of renal dysfunc-
tion, and there is a strong relationship between the severity of cirrhosis and renal
dysfunction. It has been estimated that more than 20% of patients hospitalized for
acute decompensation of cirrhosis develop acute kidney injury. Cirrhotic patients can
develop any type of renal failure, that is, prerenal (41.7%), intrarenal (38%), and
postrenal (0.3%) types [57, 58].
Hepatorenal syndrome (HRS) is a peculiar type of functional AKI described in
advanced liver disease with ascites and is characterized by vasoconstriction that does
not improve with volume replacement. Hepatorenal syndrome accounts for 20% of
AKI in patients with cirrhosis. The incidence of HRS in the natural history of cirrhosis
is 18% after 1 year and 39% after 5 years [59].
AKI in the cirrhosis spectrum is defined using the KDIGO criteria, and the interna-
tional ascites club introduces this definition of serum creatinine increase of ≥0.3 mg/
dL within 48 hours in hospitalized patients or an increase of ≥50% in 7 days [60].
19
Updates on Hemodialysis

The multiple mechanisms that condition this pathology, and the following mecha-
nisms are mentioned:

• Intrahepatic hemodynamics: Alterations in hepatic architecture conditioned

by regeneration, fibrosis, and thrombosis nodules, together with functional
alterations due to an imbalance between the greater production of vasoconstric-
tors (endothelin, leukotriene B4, thromboxane A2, and Angiotensin II) and
less formation of local vasodilators (nitric oxide, cannabinoids) determine the
development of portal hypertension and splanchnic vasodilation, which allows
the sequestration of blood in this territory [61].

• Hepatorenal reflex: The presence of sensors in intrahepatic sinusoids that are

stimulated based on changes in portal pressure and flow is mentioned. The
increase in pressure would condition the sending of a signal by the afferent sym-
pathetic nerve in the direction of the brain and the efferent sympathetic response
at the renal level. It causes vasoconstriction of the efferent arteriole [62].

• Systemic hemodynamics: It is mentioned that a determining factor is the

increase in systemic vasodilators, such as nitric oxide, among others, and the
sequestration of blood in the splanchnic territory generates an effective decrease
in blood volume that stimulates an increase in cardiac output, in order to restore
effective arterial blood volume. When the liver disease progresses, severe portal
hypertension develops and, together with bacterial translocation that mediates
the release of PAMPs into the circulation, increases the inflammatory response
that facilitates greater splanchnic vasodilation, causing a lower effective arterial
blood volume and the consequent activation of the renin-angiotensin-aldoste-
rone system, which facilitates the reabsorption of sodium and water, likewise
this neurohumoral mechanism favors renal vasoconstriction. It is important to
mention that relative hypotension stimulates the non-osmotic release of ADH,
favoring the reabsorption of water in the collecting ducts [63].

• Cirrhotic cardiomyopathy: It is described in an experimental model [64] that

in cirrhotic rats a severe blockage of the contractile capacity is generated by the
α-adrenergic agonist isoproterenol and the limited capacity to generate the cAMP
that stimulates the second messenger. The β-adrenergic receptor is the main
determinant of ventricular contractility and experimental studies show a lower
density and function of these receptors in patients with cirrhosis. It has been
shown that NO inhibits β-adrenergic receptors, altering cardiac stimulation and
decreasing cardiac contractility [65]. Endocannabinoids are also increased in
patients with cirrhosis, and they can exert a negative inotropic effect in humans.
It is described that the cardiac index <1.5 L and MAP <80 mmHg (p = < 0.05) are
the predictors of hepatorenal syndrome in a 12-month follow-up [66].

• Inflammatory response: In cirrhosis, damaged hepatocytes release DAMPs such as

high-mobility group box-1 (HMGB1), histones, and activate Kuppfer cells, leading
to the production of proinflammatory mediators such as TNF-α, IL-1α, and IL. -6.
These proinflammatory signals are detected by the intestinal immune system, and
DAMPs bind to TLRs, intestinal Paneth cells, and dendritic cells. The inflammatory
response is not limited to the liver; proinflammatory cytokines leak out and bind to
TLR 2–4 in tubular cells, generating a damaging effect at the tubular level [67].
20
Artificial Liver Support Systems
DOI: [Link]

• Relative adrenal insufficiency: It is attributed by hormonal depletion in the

hypothalamic-pituitary axis, adrenal, inflammatory, or ischemic damage,
which is present in 80% of patients with cirrhosis with HRS compared to 30%
with normal renal function, and this suggests a hormonal role in the HRS
development [62].

• Intra-abdominal pressure–intra-abdominal hypertension: An experimental

study in mice shows that intra-abdominal pressure from 10 to 20 mmHg is
associated with higher levels of urea nitrogen and creatinine and the histological
findings found report of tubular obstruction due to casts and inflammation and
interstitial edema [62].

See Figure 13.

Figure 13.
Pathophysiological mechanisms of hepatorenal syndrome. A) The greater production of vasoconstrictors and less
formation of local vasodilators determine the development of portal hypertension and splanchnic vasodilation,
which allows the sequestration of blood in this territory. Splanchnic vasodilation generates an effective decrease
in blood volume that stimulates an increase in cardiac output, in order to restore effective arterial blood
volume. When the liver disease progresses, severe portal hypertension develops and, together with the bacterial
translocation that mediates the release of PAMPs into the circulation, increases the inflammatory response that
facilitates greater splanchnic vasodilation, causing a lower effective arterial blood volume and the consequent
activation of the sympathetic and renin-angiotensin-aldosterone system, which facilitates the reabsorption of
sodium and water, B) cirrhotic cardiomyopathy, there are multiple mechanisms that allow its development and
condition a decrease in cardiac output, which conditions a decrease in mean arterial pressure, being a predictor
of the development of hepatorenal syndrome. C) Bacterial overgrowth and bacterial translocation allow PMAPs
to reach the enterohepatic circulation and precipitating factors and the progression of liver damage from the
underlying disease allows the release of DAMPS, and both molecular patterns are presented to both Kupffer cells
generating an intrahepatic inflammatory response and the presentation of these molecular patterns to dendritic
cells and macrophages facilitates SIRS, the arrival of PAMPs and DAMPs to the kidneys allows them to filter
and be captured by TLR2-4 of tubular cells, generating a damaging effect. D) Relative adrenal insufficiency that
determines hemodynamic changes. E) Increased intra-abdominal pressure due to ascites, associated with changes
in intrarenal hemodynamics such as renal venous congestion.

21
Updates on Hemodialysis

14.1 Diagnosis

The diagnosis of hepatorenal syndrome is difficult and is made by ruling out since
there is no laboratory or imaging study to confirm it with certainty.
Within the International Ascites Club criteria, defines AKI as increases in serum
creatinine of ≥ 0.3 mg/dL within 48 hours or 50% increase within 7 days in hospital-
ized patients with no response after 2 days consecutive with the use of albumin (1 g/
kg of body weight), in the absence of shock, without the use of nephrotoxic drugs,
absence of proteinuria (> 500 mg/day), absence of microhematuria (> 50 red blood
cells per high-power field), and normal findings on renal ultrasound [60].
The aforementioned criteria should be reviewed because many patients with
cirrhosis usually present hypotension without being in septic shock, and the pres-
ence of hematuria and proteinuria may be present secondary to IgA nephropathy
or membranoproliferative glomerulonephritis due to C virus, and it should be
considered that they are also exposed to use of antibiotics and analgesics. I believe
that many of them have overlapping causes within the spectrum of hepatorenal
syndrome [68].
In the analysis, there is no pathognomonic marker. In the past, it was reported that
FENA <1% was an indicator of this disease; currently, the cutoff value seems to be
lower <0.2% [69], in the advent of biomarkers the urinary NGAL <400 μg/L cor-
relates with hepatorenal syndrome, and urinary NAGAL values >400 μg/L occur in
acute tubular necrosis (ATN) [70].

14.2 Treatment

The initial treatment of AKI in the spectrum of cirrhosis is the use of albumin
(1 g/kg of body weight) for 48 hours. Velez et. al [71] describe AKI phenotypes
in cirrhosis based on the diameter of the inferior vena cava (IVC) evaluated by
ultrasound, in the aforementioned work three groups are described: group with IVC
diameter <1.3 cm, which is subdivided According to CVI collapse, it can be > 40%,
which corresponds to the fluid depleted phenotype and this group would benefit
from albumin replacement; in those with <40% collapse, it corresponds to the intra-
abdominal hypertension phenotype and would benefit from paracentesis. In the
second group with IVC 1.3-2 cm corresponds to the fluid repleted phenotype, which
would benefit from vasoconstrictors and in the third group corresponds to those
with IVC > 2 cm and which is subdivided based on collapse >40% indicating a state
of euvolemia, the use of vasoconstrictors would be a good therapeutic option and
those with collapsibility <40% correspond to the fluid expanded phenotype where
diuretics are indicated.
If after expansion with albumin the decrease in creatinine is not achieved,
albumin should be maintained at 20–40 g and add Terlipressin 0.5–1 mg/4–6 hours,
titrating the dose with 2-mg increment every day until reaching a maximum dose
of 12 mg, an adequate response is defined when a 25% drop in initial creatinine is
achieved, and in case of no response, Terlipressin can be administered for 14 days. It
is recommended that infusion is better when compared with boluses every 6 hours.
The predictive factors of poor response to Terlipressin are elevated total bilirubin
values >10 mg/dl, lack of MAP increase of 5 mmHg on day 3, as well as NGAL
>728 μg/L. (61.63).
The evidence on Terlipressin, norepinephrine, octreotide, and midodrine is
extensive and exceeds the scope of the review.
22
Artificial Liver Support Systems
DOI: [Link]

15. Renal support therapies in hepatorenal syndrome

The use of renal supportive therapy is indicated when patients with hepatorenal
syndrome develop absolute indications for renal supportive therapy (RST) (severe
metabolic acidosis, severe hyperkalemia, fluid overload, encephalopathy, and uremia)
in nonresponders to the use of Terlipressin with albumin.
AKI, due to HRS and ATN, has a poor prognosis because 40% require RST and
60% die within 90 days [72]. In a retrospective cohort of 472 patients with diagnoses
of HRS and ATN, 341 of these did not enter the waiting list and 131 were included on
the waiting list. It was evident that those who developed HRS presented higher SOFA
and MELD scores and patients with ATN presented sepsis and required vasopressors
and mechanical ventilation. The 6-month survival for those who were not placed on
the waiting list with HRS (84%) and ATN (85%) was similar. The RST start is contro-
versial in patients who are not candidates for liver transplantation because it does not
modify the prognosis.
At this point, three scenarios are proposed [73]:

1. The patient is included in the waiting list and the need for RST becomes a bridge
until the transplant, in this case, there is no doubt of the benefit.

2. The second scenario is a patient in the evaluation phase for liver transplantation,
where the need for RST will be until the inclusion on the list is clear.

3. In those who are not included on the waiting list for liver transplantation, can
receive RST temporarily or until the experts in palliative care, the patient and the
family decide they will limit efforts in a terminal illness.

16. Conclusions

ALF and ACLF represent very complex pathophysiological diseases that encom-
pass multiple inflammation mechanisms that perpetuate liver damage and medi-
cal treatment is not successful in limiting the damage. The use of albumin-based
extracorporeal support therapies has not been shown to have an impact on survival
and we see plasma exchange therapies or therapies combined with hemoperfusion
show better survival than the traditional ones, although more randomized controlled
trials with a greater number of patients are needed of patients to have a stronger
recommendation.
Hepatorenal syndrome is a renal complication in patients with advanced liver cir-
rhosis and is triggered by multiple mechanisms. There is no gold standard for diag-
nosis, which is by exclusion, albumin and Terlipressin therapy is the recommended
treatment in response to treatment with higher mortality, which is not modified by
the use of renal support therapies.

23
Updates on Hemodialysis

Author details

Maiko Alejandro Tavera Díaz

Nephrology Department, Univalle Hospital, Bolivia

*Address all correspondence to: taveradiaz@[Link]

© 2023 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of
the Creative Commons Attribution License ([Link]
which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly cited.
24
Artificial Liver Support Systems
DOI: [Link]

References

[1] Asrani SK, Devarbhavi H, Eaton J, New England Journal of Medicine.

Kamath PS, et al. Burden of liver diseases 2020;382(22):2137-2145. Available from:
in the world. Journal of Hepatology. DOI: 10.1056/NEJMra1914900
2019;70(1):151-171. Available from:
DOI: 10.1016/[Link].2018.09.014 [9] Bernsmeier C, Antoniades CG,
Wendon J, et al. What's new in acute
[2] Sarin SK, Choudhury A, et al. liver failure? Intensive Care Medicine.
Acute-on-chronic liver failure. 2014;40(10):1545-1548. Available from:
Current Gastroenterology Reports. DOI: 10.1007/s00134-014-3350-4
2016;18(12):61. Available from:
DOI: 10.1007/s11894-016-0535-8 [10] Craig DG, Lee P, Pryde EA,
Hayes PC, Simpson KJ, et al. Serum
[3] Weiler N, Schlotmann A, neopterin and soluble CD163 as markers
Schnitzbauer AA, Zeuzem S, Welker MW, of macrophage activation in paracetamol
et al. The epidemiology of acute (acetaminophen)-induced human acute
liver failure. Deutsches Ärzteblatt liver injury. Alimentary Pharmacology &
International. 2020;117(4):43-50. Therapeutics. 2013;38(11-12):1395-1404.
Available from: DOI: 10.3238/ DOI: 10.1111/apt.12530
arztebl.2020.0043
[11] European Association for the Study
[4] Stravitz RT, Lee WM, et al. Acute liver of the Liver Clinical practice guidelines
failure. Lancet. 2019;394(10201):869- panel, Wendon J, Panel members,
881. Available from: DOI: 10.1016/ Cordoba J, Dhawan A, et al. EASL clinical
s0140-6736(19)31894-x practical guidelines on the management
of acute (fulminant) liver failure. Journal
[5] Bernal W, Wendon J, et al. Acute of Hepatology. 2017;66(5):1047-1081.
liver failure. The New England Journal [Internet] Available from: DOI: 10.1016/j.
of Medicine. 2013;369(26):2525- jhep.2016.12.003
2534. Available from: DOI: 10.1056/
NEJMra1208937 [12] Sarin SK, Choudhury A. Acute-
on-chronic liver failure: Terminology,
[6] Arroyo V, Moreau R, Kamath PS, mechanisms and management.
Jalan R, Ginès P, Nevens F, et al. Acute- Nature Reviews. Gastroenterology
on-chronic liver failure in cirrhosis. & Hepatology. 2016;13(3):131-
Nature Reviews. Disease Primers. 149. Available from: DOI: 10.1038/
2016;2(1):16041. Available from: nrgastro.2015.219
DOI: 10.1038/nrdp.2016.41
[13] Honore PM, Hoste E, Molnár Z,
[7] Bernal W, Jalan R, Quaglia A, Jacobs R, Joannes-Boyau O,
Simpson K, Wendon J, Burroughs A, Malbrain MLNG, et al. Cytokine removal
et al. Acute-on-chronic liver failure. in human septic shock: Where are we and
Lancet. 2015;386(10003):1576- where are we going? Annals of Intensive
1587. Available from: DOI: 10.1016/ Care. 2019;9(1):1-13. Available from:
S0140-6736(15)00309-8 DOI: 10.1186/s13613-019-0530-y

[8] Arroyo V, Moreau R, Jalan R, et al. [14] Carvalho JR, Machado MV, et al.
Acute-on-chronic liver failure. The New insights about albumin and
25
Updates on Hemodialysis

liver disease. Annals of Hepatology. Alterations in the functional capacity of

2018;17(4):547-560. Available from: albumin in patients with decompensated
DOI: 10.5604/01.3001.0012.0916 cirrhosis is associated with increased
mortality. Hepatology. 2009;50(2):555-
[15] Oettl K, Marsche G, et al. Redox 564. Available from: DOI: 10.1002/
state of human serum albumin in terms hep.22913
of cysteine-34 in health and disease.
Methods in Enzymology. 2010;474:181- [21] Groeneveld D, Cline-Fedewa H,
195. Available from: DOI: 10.1016/ Baker KS, Williams KJ, Roth RA,
S0076-6879(10)74011-8 Mittermeier K, et al. Von Willebrand
factor delays liver repair after
[16] Sun L, Yin H, Liu M, Xu G, Zhou X, acetaminophen-induced acute liver
Ge P, et al. Impaired albumin function: injury in mice. Journal of Hepatology.
A novel potential indicator for liver 2020;72(1):146-155. Available from:
function damage? Annals of Medicine. DOI: 10.1016/[Link].2019.09.030
2019;51(7-8):333-344. Available from:
DOI: 10.1080/07853890.2019.1693056. [22] Hugenholtz GCG, Adelmeijer J,
Meijers JCM, Porte RJ, Stravitz RT,
[17] Bernardi M, Angeli P, Claria J,
Lisman T, et al. An imbalance between
Moreau R, Gines P, Jalan R, et al.
von Willebrand factor and ADAMTS13
Albumin in decompensated cirrhosis:
in acute liver failure. Hepatology.
New concepts and perspectives. Gut.
2013;58(2):752-761. Available from:
2020;69(6):1127-1138. Available from:
DOI: 10.1002/hep.26372
DOI: 10.1136/gutjnl-2019-318843

[18] Alcaraz-Quiles J, Casulleras M, Oettl K, [23] Gustafson E, Hamad OA,

Titos E, Flores-Costa R, Duran-Güell M, Deckmyn H, Barbu A, Ekdahl KN,
et al. Oxidized albumin triggers a cytokine Nilsson B, et al. Exposure of von
storm in leukocytes through P38 mitogen- Willebrand factor on isolated hepatocytes
activated protein kinase: Role in systemic promotes tethering of platelets to
inflammation in decompensated cirrhosis. the cell surface. Transplantation.
Hepatology. 2018;68(5):1937-1952 2019;103(8):1630-1638. Available from:
Available from: [Link] DOI: 10.1097/TP.00000000000002707
[Link]/30070728/
[24] Prasanna KS, Goel A, Amirtharaj GJ,
[19] Oettl K, Stadlbauer V, Krisper P, Ramachandran A, Balasubramanian KA,
Stauber RE, et al. Effect of Mackie I, et al. Plasma von Willebrand
extracorporeal liver support by molecular factor levels predict in-hospital
adsorbents recirculating system and survival in patients with acute-on-
Prometheus on redox state of albumin chronic liver failure. Indian Journal
in acute-on-chronic liver failure. of Gastroenterology. 2016;35(6):432-
Therapeutic Apheresis and Dialysis: 440. Available from: DOI: 10.1007/
Official Peer-Reviewed Journal of the s12664-016-0708-2-
International Society for Apheresis,
the Japanese Society for Apheresis, the [25] Groeneveld DJ, Poole LG,
Japanese Society for Dialysis Therapy. Luyendyk JP, et al. Targeting von
2009;13(5):431-436. Available from: Willebrand factor in liver diseases: A
DOI: 10.1111/j.1744-9987.2009.00762.x novel therapeutic strategy? Journal
of Thrombosis and Haemostasis.
[20] Jalan R, Schnurr K, Mookerjee RP, 2021;19(6):1390-1408. Available from:
Sen S, Cheshire L, Hodges S, et al. DOI: 10.1111/jth.15312
26
Artificial Liver Support Systems
DOI: [Link]

[26] Roth K, Strickland J, Copple BL, et al. [33] Vaid A, Chweich H, Balk EM,
Regulation of macrophage activation in Jaber BL. Molecular adsorbent
the liver after acute injury: Role of the recirculating system as artificial support
fibrinolytic system. World Journal of therapy for liver failure: A meta-analysis: A
Gastroenterology. 2020;26(16):1879- meta-analysis. ASAIO Journal (American
1887. Available from: DOI: 10.3748/wjg. Society for Artificial Internal Organs:
v26.i16.1879 2012). 2012;58(1):51-59. Available from.
DOI: 10.1097/MAT.0b013e31823fd077
[27] Nielsen MC, Hvidbjerg Gantzel R,
Clària J, Trebicka J, Møller HJ, Grønbæk H,
[34] Bañares R, Ibáñez-Samaniego L,
et al. Macrophage activation markers,
Torner JM, Pavesi M, Olmedo C,
CD163 and CD206, in acute-on-chronic
Catalina MV, et al. Meta-analysis of
liver failure. Cell. 2020;9(5):1175. Available
individual patient data of albumin
from: DOI: 10.3390/cells9051175
dialysis in acute-on-chronic liver failure:
[28] Chamuleau RA. Future of Focus on treatment intensity. Therapeutic
bioartificial liver support. World Advances in Gastroenterology.
Journal of Gastrointestinal Surgery. 2019;12:1756284819879565. Available
2009;1(1):21-25. Available from: from: DOI: 10.1177/1756284819879565
DOI: 10.4240/wjgs.v1.i1.21
[35] Saliba F, Bañares R, Larsen FS,
[29] Mitzner SR, Stange J, Klamt S,
Wilmer A, Parés A, Mitzner S, et al.
Koball S, Hickstein H, Reisinger EC.
Artificial liver support in patients
Albumin dialysis MARS: Knowledge
with liver failure: A modified
from 10 years of clinical investigation.
DELPHI consensus of international
ASAIO Journal 2009 2022; 55(5):498-502.
experts. Intensive Care Medicine.
Available from: [Link]
2022;48(10):1352-1367. Available from:
[Link]/19730006/.
DOI: 10.1007/s00134-022-06802-1
[30] Tandon R, Froghi S, et al. Artificial
liver support systems. Journal of [36] Kribben A, Gerken G, Haag S,
Gastroenterology and Hepatology. Herget-Rosenthal S, Treichel U, Betz C,
2021;36(5):1164-1179. Available from: et al. Effects of fractionated plasma
DOI: 10.1111/jgh.15255 separation and adsorption on survival
in patients with acute-on-chronic
[31] Saliba F, Camus C, Durand F,
liver failure. Gastroenterology.
Mathurin P, Letierce A, Delafosse B, et al.
2012;142(4):782-789.e3. Available from:
Albumin dialysis with a noncell artificial
DOI: 10.1053/[Link].2011.12.056
liver support device in patients with acute
liver failure: A randomized, controlled trial:
[37] Stadlbauer V, Krisper P, Aigner R,
A randomized, controlled trial. Annals of
Haditsch B, Jung A, Lackner C, et al.
Internal Medicine. 2013;159(8):522-531.
Effect of extracorporeal liver support
Available from: DOI: 10.7326/0003-4819-
by MARS and Prometheus on serum
159-8-201310150-00005
cytokines in acute-on-chronic liver
[32] Bañares R, Nevens F, Larsen FS, failure. Critical Care. 2006;10(6):R169.
Jalan R, Albillos A, Dollinger M, et al. Available from: DOI: 10.1186/cc5119
Extracorporeal albumin dialysis with
the molecular adsorbent recirculating [38] Sen S, Davies NA, Mookerjee RP,
system in acute-on-chronic liver Cheshire LM, Hodges SJ, Williams R,
failure: The RELIEF trial. Hepatology. et al. Pathophysiological effects of
2013;57(3):1153-1162. Available from: albumin dialysis in acute-on-chronic liver
DOI: 10.1002/hep.26185 failure: A randomized controlled study.
27
Updates on Hemodialysis

Liver Transplantation, Available from. liver failure: An open randomized

2004;10:1109-1119. DOI: 10.1002/lt.20236 controlled trial. Journal of Hepatology.
2016;64(1):69-78. Available from:
[39] Rifai K, Ernst T, Kretschmer U, DOI: 10.1016/[Link].2015.08.018
Haller H, Manns MP, Fliser D. Removal
selectivity of Prometheus: A new [45] Maiwall R, Bajpai M, Singh A,
extracorporeal liver support device. Agarwal T, Kumar G, Bharadwaj A, et al.
World Journal of Gastroenterology. Standard-volume plasma exchange
2006;12:940-944. Available from: improves outcomes in patients with acute
DOI: 10.3748/wjg.v12.i6.940 liver failure: A randomized controlled trial.
Clinical Gastroenterology and Hepatology:
[40] Sponholz C, Matthes K, Rupp D, The Official Clinical Practice Journal of the
Backaus W, Klammt S, Karailieva D, American Gastroenterological Association.
et al. Molecular adsorbent recirculating 2022;20(4):e831-e854. Available from:
system and single-pass albumin DOI: 10.1016/[Link].2021.01.036
dialysis in liver failure--a prospective,
randomized crossover study. Critical [46] Kumar SE, Goel A, Zachariah U,
Care. 2016;20(1):2. Available from: Nair SC, David VG, Varughese S, et al.
DOI: 10.1186/s13054-015-1159-3 Low volume plasma exchange and low
dose steroid improve survival in patients
[41] Benyoub K, Muller M, Bonnet A, with alcohol-related acute on chronic
Simon R, Gazon M, Duperret S, et al. liver failure and severe alcoholic hepatitis
Amounts of bile acids and bilirubin - preliminary experience. Journal of
removed during single-pass albumin Clinical and Experimental Hepatology.
dialysis in patients with liver failure: 2022;12(2):372-378. Available from:
Letters to the editor. Therapeutic DOI: 10.1016/[Link].2021.07.010
Apheresis and Dialysis. 2011;15(5):
504-506. Available from: https:// [47] Ocskay K, Kanjo A, Gede N,
[Link]/21974706/ Szakács Z, Pár G, Erőss B, et al.
Uncertainty in the impact of liver
[42] Wallon G, Guth C, Guichon C, support systems in acute-on-chronic liver
Thevenon S, Gazon M, Viale J-P, et al. failure: A systematic review and network
Extracorporeal albumin dialysis in meta-analysis. Annals of Intensive Care.
liver failure with MARS and SPAD: 2021;11(1):10 Available from: https://
A randomized crossover trial. Blood [Link]/33462764/
Purification. 2022;51(3):243-250.
Available from: DOI: 10.1159/000515825 [48] Du L, Ma Y, Zhou S, Chen F, Xu Y,
Wang M, et al. A prognostic score for
[43] Stahl K, Schmidt JJ, Seeliger B, patients with acute-on-chronic liver
Schmidt BMW, Welte T, Haller H, et al. failure treated with plasma exchange-
Effect of therapeutic plasma exchange on centered artificial liver support system.
endothelial activation and coagulation- Scientific Reports. 2021;11(1):1469
related parameters in septic shock. Critical Available from: [Link]
Care. 2020, 2020;24(1):71. Available from. articles/s41598-021-81019-8
DOI: 10.1186/s13054-020-2799-5
[49] Viggiano D, de Pascale E,
[44] Larsen FS, Schmidt LE, Marinelli G, Pluvio C, et al. A
Bernsmeier C, Rasmussen A, Isoniemi H, comparison among three different
Patel VC, et al. High-volume plasma apheretic techniques for treatment of
exchange in patients with acute hyperbilirubinemia. Journal of artificial
28
Artificial Liver Support Systems
DOI: [Link]

organs: The official journal of the [55] Ronco C, Bellomo R. Sorbents: From
Japanese society for. Artificial Organs. Basic Structure to Clinical Application.
2018;21(1):110-116. Available from: In: Ronco C, Bellomo R, editors. Critical
DOI: 10.1007/s10047-017-0986-1 Care Nephrology. Elsevier Health
Sciences. 2017:1137-1154.e2
[50] Wan Y-M, Li Y-H, Xu Z-Y,
Yang J, Yang L-H, Xu Y, et al. Therapeutic [56] Kittanamongkolchai W,
plasma exchange versus double plasma El-Zoghby ZM, Eileen Hay J, Wiesner RH,
molecular absorption system in hepatitis Kamath PS, LaRusso NF, et al. Charcoal
B virus-infected acute-on-chronic hemoperfusion in the treatment of
liver failure treated by entercavir: A medically refractory pruritus in cholestatic
prospective study. Journal of Clinical liver disease. Hepatology International.
Apheresis. 2017;32(6):453-461. Available 2017;11(4):384-389. Available from:
from: DOI: 10.1002/jca.21535 DOI: 10.1007/s12072-016-9775-9

[51] Ma L, Zhang X, Ma W, Ding X, et al. [57] Dominik A, Stange J, et al.

Meta-analysis of the efficacy of DPMAS- Similarities, differences, and potential
based artificial liver in the treatment of synergies in the mechanism of action
ACLF. Research Square. 28 April 2022. of albumin dialysis using the MARS
Available from: [Link] albumin dialysis device and the CytoSorb
[Link]-1604197/v1 hemoperfusion device in the treatment
of liver failure. Blood Purification.
[52] Bai W, Yao C, Mao D, Wu J, Wang K, 2021;50(1):119-128. Available from:
Wei H, et al. The clinical efficacy of double DOI: 10.1159/000508810
plasma molecular absorption system
[58] Angeli P, Merkel C, et al.
combined with plasma exchange in the
Pathogenesis and management of
treatment of acute-on-chronic liver failure:
hepatorenal syndrome in patients
A systematic review and meta-analysis.
with cirrhosis. Journal of Hepatology.
Journal of Healthcare Engineering.
2008;48(Suppl. 1):S93-S103. Available
2022;2022:3139929 Available from: https://
from: DOI: 10.1016/[Link].2008.01.010
[Link]/35368957/
[59] Ginès A, Escorsell A, Ginès P, Saló J,
[53] Yao J, Li S, Zhou L, Luo L, Yuan L, Jiménez W, Inglada L, et al. Incidence,
Duan Z, et al. Therapeutic effect of predictive factors, and prognosis of
double plasma molecular adsorption the hepatorenal syndrome in cirrhosis
system and sequential half-dose plasma with ascites. Gastroenterology.
exchange in patients with HBV-related 1993;105(1):229-236. Available from:
acute-on-chronic liver failure. Journal of DOI: 10.1016/0016-5085(93)90031-7
Clinical Apheresis. 2019;34(4):392-398
Available from: [Link] [60] Angeli P, Garcia-Tsao G, Nadim MK,
[Link]/30758886/ Parikh CR, et al. News in pathophysiology,
definition and classification of
[54] Donati G, Angeletti A, Gasperoni L, hepatorenal syndrome: A step beyond
Piscaglia F, Croci Chiocchini AL, Scrivo A, the International Club of Ascites
et al. Detoxification of bilirubin and (ICA) consensus document. Journal of
bile acids with intermittent coupled Hepatology. 2019;71(4):811-822. Available
plasmafiltration and adsorption in liver from: DOI: 10.1016/[Link].2019.07.002
failure (HERCOLE study). Journal of
Nephrology. 2021;34(1):77-88. Available [61] Martell M, Coll M, Ezkurdia N,
from: DOI: 10.1007/s40620-020-00799-w Raurell I, Genescà J, et al. Physiopathology
29
Updates on Hemodialysis

of splanchnic vasodilation in portal 2020;16(3):137-155. Available from:

hypertension. World. Journal of DOI: 10.1038/s41581-019-0218-4
Hepatology. 2010;2(6):208-220. Available
from: DOI: 10.4254/wjh.v2.i6.208 [69] Varghese V, Rivera MS, Alalwan A,
Alghamdi AM, Ramanand A, Khan SM,
[62] Hasan I, Rashid T, Chirila RM, et al. Concomitant identification of
Ghali P, Wadei HM, et al. Hepatorenal muddy brown granular casts and low
syndrome: Pathophysiology and fractional excretion of urinary sodium
evidence-based management update. in AKI. Kidney 360. 2022;3(4):627-
Revue Roumaine de. Médecine Interne. 635. Available from: DOI: 10.34067/
2021;59(3):227-261. Available from: KID.0005692021
DOI: 10.2478/rjim-2021-0006
[70] Yang CC, Hsieh SC, Li KJ, Wu CH,
[63] Ginès P, Schrier RW, et al. Renal Lu MC, Tsai CY, et al. Urinary neutrophil
failure in cirrhosis. The New England gelatinase-associated lipocalin is a
Journal of Medicine. 2009;361(13):1279- potential biomarker for renal damage
1290. Available from: DOI: 10.1056/ in patients with systemic lupus
NEJMra0809139 erythematosus. Journal of Biomedicine
& Biotechnology. 2012;2012:759313
[64] Ward CA, Liu H, Lee SS, et al. Available from: [Link]
Altered cellular calcium regulatory [Link]/22500106
systems in a rat model of cirrhotic
cardiomyopathy. Gastroenterology. [71] Velez JCQ , Petkovich B,
2001;121(5):1209-1218. Available from: Karakala N, Huggins JT et al.
DOI: 10.1053/gast.2001.28653 Point-of-care echocardiography reveals
misclassification of acute kidney
[65] Bernardi M. Cirrhotic injury as hepatorenal syndrome.
cardiomyopathy. Clinics in Liver Disease. American Journal of Nephrology
2013;2(3):99-101. Available from: 2019;50(3): 204-211. Available from:
DOI: 10.1002/cld.141 doi:10.1159/000501299

[66] Krag A, Bendtsen F, Henriksen JH, [72] Allegretti AS, Parada XV,
Møller S, et al. Low cardiac output Eneanya ND, Gilligan H, Xu D, Zhao S,
predicts development of hepatorenal et al. Prognosis of patients with cirrhosis
syndrome and survival in patients and AKI who initiate RRT. Clinical
with cirrhosis and ascites. Gut. Journal of the American Society of
2010;59(1):105-110. Available from: Nephrology. 2018;13(1):16-25. Available
DOI: 10.1136/gut.2009.180570 from: DOI: 10.2215/CJN.03610417

[67] Fukazawa K, Lee HT, et al. Updates [73] JCQ V. Patients with hepatorenal
on hepato-renal syndrome. Journal syndrome should be dialyzed? PRO.
of Anesthesia & Clinical Research. Kidney 360. 2021;2(3):406-409 Available
2013;4(9):352. Available from: from: [Link]
DOI: 10.4172/2155-6148.1000352 content/2/3/[Link]

[68] Velez JCQ , Therapondos G,

Juncos LA, et al. Reappraising the
spectrum of AKI and hepatorenal
syndrome in patients with cirrhosis.
Nature reviews. Nephrology.
30